title: [Comparison of MGMT and ERCC₂ expression in temozolomide for the treatment of malignant glioma drug resistance and their genetic relationship].
abstract: OBJECTIVE
  To study the impact of two human glioma tissue resistance genes MGMT and ERCC(2) on the temozolomide-based treatment of malignant gliomas and detect the relationship of their expressions.
  
  
  METHODS
  A total of 58 malignant glioma patients aged 19 - 68 years old receiving a chemotherapy of temozolomide were followed up and classified as non-sensitive group (n = 30) and sensitive group (n = 28). Immunohistochemistry was employed to detect the expression rates of MGMT and ERCC(2). And the correlation between the expressions of two genes was analyzed by immunohistochemistry and RT-PCR (reverse transcription-polymerase chain reaction).
  
  
  RESULTS
  The expression rates of MGMT and ERCC(2) were 10.71% and 3.57% in the sensitive group and 63.33% and 56.67% in the non-sensitive group. It had an obvious correlation with the expressions of MEGT and ERCC(2) through an analysis of immunohistochemistry and RT-PCR (both P < 0.01).
  
  
  CONCLUSIONS
  The expressions of MGMT and ERCC(2) in the sensitive group are markedly lower than those in the non-sensitive group. The expression of two genes may be related to tumor prognosis. Maybe these two genes have an intrinsic link between their expressions. Both participate in the repair of cellular DNA damage and the formation of tumor drug resistance. And the prognosis has obvious relevance.
authors.affiliation: Department of Neurosurgery, Second Affiliated Hospital, Harbin Medical University, Harbin 150086, China.
authors.forename: Xu
authors.initials: X
authors.lastname: Hou
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhao
authors.forename: Yong-Ri
authors.initials: YR
authors.lastname: Zheng
authors.forename: Jian-Jiao
authors.initials: JJ
authors.lastname: Wang
authors.forename: Zhi-Chao
authors.initials: ZC
authors.lastname: Wu
authors.forename: Jia-Hang
authors.initials: JH
authors.lastname: Sun
mesh_terms: D000328:Adult; D000368:Aged; D001932:Brain Neoplasms / Q000188:drug therapy / Q000235:genetics; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D015870:Gene Expression; D005809:Genes, Regulator; D005910:Glioma / Q000188:drug therapy / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D019853:O(6)-Methylguanine-DNA Methyltransferase / Q000235:genetics*; D000077204:Temozolomide; D051759:Xeroderma Pigmentosum Group D Protein / Q000235:genetics*; D055815:Young Adult
chemical_list: D003606:Dacarbazine; D019853:O(6)-Methylguanine-DNA Methyltransferase; D051759:Xeroderma Pigmentosum Group D Protein; C497292:ERCC2 protein, human; D000077204:Temozolomide